Edge Rewrite
restyle Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

Aleph (psychedelic)

From Wikipedia, the free encyclopedia
(Redirected from Aleph-x)
Aleph
Clinical data
Other namesAleph; Aleph-1; ALEPH; ALEPH-1; DOT; DOT-1; Para-DOT; 4-Methylthio-2,5-dimethoxyamphetamine; 2,5-Dimethoxy-4-methylthioamphetamine; 4-MeS-DMA; 4-Thio-TMA-2
Routes of
administration		Oral[1]
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Pharmacokinetic data
Duration of action6–8 hours[1]
Identifiers
  • 1-[2,5-dimethoxy-4-(methylsulfanyl)phenyl]propan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H19NO2S
Molar mass241.35 g·mol−1
3D model (JSmol)
  • C1(=C(C=C(C(=C1)SC)OC)CC(C)N)OC
  • InChI=1S/C12H19NO2S/c1-8(13)5-9-6-11(15-3)12(16-4)7-10(9)14-2/h6-8H,5,13H2,1-4H3 checkY
  • Key:COBYBOVXXDQRAU-UHFFFAOYSA-N checkY
  (verify)

Aleph, or ALEPH-1, also known as DOT or para-DOT or as 4-methylthio-2,5-dimethoxyamphetamine, is a psychedelic drug of the phenethylamine, amphetamine, and DOx families.[1] It is one of the Aleph series of compounds.[1]

Use and effects

[edit source]

In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists Aleph's dose range as 5 to 10 mg orally and its duration as 6 to 8 hours.[1] The effects of Aleph have been reported to include simple tasks feeling "alien", intense intellectual stimulation, impairment, a sensation of pleasant physical warmth, and an afterglow including feelings of empathy for everything.[1]

Interactions

[edit source]

Pharmacology

[edit source]

Pharmacodynamics

[edit source]

Aleph is known to be a superagonist of the serotonin 5-HT2A receptor (EC50Tooltip half-maximal effective concentration = 10–66 nM; EmaxTooltip maximal efficacy = 114–191%).[2][3]

It has weak MAO-A inhibitory activity with an IC50Tooltip half-maximal inhibitory concentration of 5.2 μM.[4] For comparison, amphetamine has an IC50 of 11 μM and 4-methylthioamphetamine (4-MTA) has a value of 0.2 μM.[4]

Chemistry

[edit source]

Synthesis

[edit source]

The chemical synthesis of Aleph has been described.[1]

Derivatives

[edit source]

Derivatives of Aleph include Aleph-2, Aleph-4, Aleph-6, and Aleph-7.[1] The Aleph series of compounds are the DOx or amphetamine analogues of 2C-T, 2C-T-2, 2C-T-4, 2C-T-6, and 2C-T-7, respectively.[1]

History

[edit source]

Aleph was first tested by Alexander Shulgin in 1975.[1] It was first described in the scientific literature by Shulgin and David E. Nichols in 1976.[5][6] Its properties and effects in humans were described by them in 1978.[7] Subsequently, the drug was described in greater detail by Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).[1]

Society and culture

[edit source]

Names

[edit source]

Aleph was named by Alexander Shulgin, who named it after the first letter of the Hebrew alphabet.[1] Another earlier name of the drug is para-DOT.[1][7]

[edit source]

Canada

[edit source]

Aleph is a controlled substance in Canada under phenethylamine blanket-ban language.[8]

United States

[edit source]

In the United States, Aleph is a Schedule 1 controlled substance as a positional isomer of 2C-T-4 and 2C-T-7.[9]

See also

[edit source]

References

[edit source]
  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 Shulgin, Alexander; Shulgin, Ann (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628. https://erowid.org/library/books_online/pihkal/pihkal003.shtml
  2. ↑ Halberstadt AL, Luethi D, Hoener MC, Trachsel D, Brandt SD, Liechti ME (January 2023). "Use of the head-twitch response to investigate the structure-activity relationships of 4-thio-substituted 2,5-dimethoxyphenylalkylamines". Psychopharmacology. 240 (1): 115–126. doi:10.1007/s00213-022-06279-2. PMC 9816194. PMID 36477925.
  3. ↑ Pottie E, Poulie CB, Simon IA, Harpsøe K, D'Andrea L, Komarov IV, Gloriam DE, Jensen AA, Kristensen JL, Stove CP (August 2023). "Structure-Activity Assessment and In-Depth Analysis of Biased Agonism in a Set of Phenylalkylamine 5-HT2A Receptor Agonists". ACS Chem Neurosci. 14 (15): 2727–2742. doi:10.1021/acschemneuro.3c00267. hdl:1854/LU-01HKSP4M4EAJW6K41YXJ05T517. PMID 37474114.
  4. 1 2 Gallardo-Godoy A, Fierro A, McLean TH, Castillo M, Cassels BK, Reyes-Parada M, Nichols DE (April 2005). "Sulfur-substituted alpha-alkyl phenethylamines as selective and reversible MAO-A inhibitors: biological activities, CoMFA analysis, and active site modeling". Journal of Medicinal Chemistry. 48 (7): 2407–2419. doi:10.1021/jm0493109. PMID 15801832.
  5. ↑ Nichols DE, Shulgin AT (October 1976). "Sulfur analogs of psychotomimetic amines". J Pharm Sci. 65 (10): 1554–1556. doi:10.1002/jps.2600651040. PMID 978423.
  6. ↑ Jacob P, Anderson G, Meshul CK, Shulgin AT, Castagnoli N (October 1977). "Monomethylthio analogues of 1-(2,4,5-trimethoxyphenyl)-2-aminopropane". J Med Chem. 20 (10): 1235–1239. doi:10.1021/jm00220a001. PMID 903913.
  7. 1 2 Shulgin AT, Nichols DE (1978). "Characterization of Three New Psychotomimetics". In Stillman RC, Willette RE (eds.). The Psychopharmacology of Hallucinogens. Elsevier. pp. 74–83. doi:10.1016/b978-0-08-021938-7.50010-2. ISBN 978-0-08-021938-7.
  8. ↑ "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.
  9. ↑ "Lists of: Scheduling Actions Controlled Substances Regulated Chemicals" (PDF). Drug and Chemical Evaluation Section, Diversion Control Division. Drug Enforcement Administration, U.S. Department of Justice. January 2023.
[edit source]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Aleph_(psychedelic)&oldid=1361145854#Derivatives"